Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carsten Bokemeyer

Showing results (331-340 of 664) with videos related to

Pageof 67
Sort By:
World Journal of Urology|January 22, 2004
The role of [(18)F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of post chemotherapy residual masses in metastatic germ cell tumors--prospects for managementAnna C Pfannenberg, Karin Oechsle, Carsten Bokemeyer, et al.
European Urology|August 23, 2015
Guidelines on Testicular Cancer: 2015 UpdatePeter Albers, Walter Albrecht, Ferran Algaba, et al.
Frontiers in Medicine|November 25, 2021
Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and MyelomaFranziska Brauneck, Pauline Weimer, Julian Schulze Zur Wiesch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2009
Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myelomaDjordje Atanackovic, Tim Luetkens, York Hildebrandt, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 9, 2010
Amplification of 8q21 in breast cancer is independent of MYC and associated with poor patient outcomeMatthias Choschzick, Paula Lassen, Annette Lebeau, et al.
European Urology|April 3, 2012
The contemporary role of chemotherapy for advanced testis cancer: a systematic review of the literatureFabio Calabrò, Peter Albers, Carsten Bokemeyer, et al.
Oral Oncology|June 15, 2012
Epidermal growth factor receptor (EGFR) in salivary gland carcinomas: potentials as therapeutic targetTill Sebastian Clauditz, Artur Gontarewicz, Patrick Lebok, et al.
International Journal of Molecular Sciences|December 10, 2021
Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AMLFranziska Brauneck, Elisa Seubert, Jasmin Wellbrock, et al.
Journal of Cancer Survivorship : Research and Practice|November 4, 2021
Evaluation of an electronic psycho-oncological adaptive screening program (EPAS) with immediate patient feedback: findings from a German cluster intervention studyPeter Esser, Leon Sautier, Susanne Sarkar, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 24, 2010
Miliary never-smoking adenocarcinoma of the lung: strong association with epidermal growth factor receptor exon 19 deletionEckart Laack, Ronald Simon, Marc Regier, et al.
Pageof 67

Showing results (331-340 of 664) with videos related to

Sort By:
Pageof 67
World Journal of Urology|January 22, 2004
The role of [(18)F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of post chemotherapy residual masses in metastatic germ cell tumors--prospects for managementAnna C Pfannenberg, Karin Oechsle, Carsten Bokemeyer, et al.
European Urology|August 23, 2015
Guidelines on Testicular Cancer: 2015 UpdatePeter Albers, Walter Albrecht, Ferran Algaba, et al.
Frontiers in Medicine|November 25, 2021
Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and MyelomaFranziska Brauneck, Pauline Weimer, Julian Schulze Zur Wiesch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2009
Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myelomaDjordje Atanackovic, Tim Luetkens, York Hildebrandt, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 9, 2010
Amplification of 8q21 in breast cancer is independent of MYC and associated with poor patient outcomeMatthias Choschzick, Paula Lassen, Annette Lebeau, et al.
European Urology|April 3, 2012
The contemporary role of chemotherapy for advanced testis cancer: a systematic review of the literatureFabio Calabrò, Peter Albers, Carsten Bokemeyer, et al.
Oral Oncology|June 15, 2012
Epidermal growth factor receptor (EGFR) in salivary gland carcinomas: potentials as therapeutic targetTill Sebastian Clauditz, Artur Gontarewicz, Patrick Lebok, et al.
International Journal of Molecular Sciences|December 10, 2021
Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AMLFranziska Brauneck, Elisa Seubert, Jasmin Wellbrock, et al.
Journal of Cancer Survivorship : Research and Practice|November 4, 2021
Evaluation of an electronic psycho-oncological adaptive screening program (EPAS) with immediate patient feedback: findings from a German cluster intervention studyPeter Esser, Leon Sautier, Susanne Sarkar, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 24, 2010
Miliary never-smoking adenocarcinoma of the lung: strong association with epidermal growth factor receptor exon 19 deletionEckart Laack, Ronald Simon, Marc Regier, et al.
Pageof 67